CN1905880A - 包含有机化合物的组合物 - Google Patents

包含有机化合物的组合物 Download PDF

Info

Publication number
CN1905880A
CN1905880A CNA2004800409427A CN200480040942A CN1905880A CN 1905880 A CN1905880 A CN 1905880A CN A2004800409427 A CNA2004800409427 A CN A2004800409427A CN 200480040942 A CN200480040942 A CN 200480040942A CN 1905880 A CN1905880 A CN 1905880A
Authority
CN
China
Prior art keywords
weight
compositions
agent
hpmc
pitavastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800409427A
Other languages
English (en)
Chinese (zh)
Inventor
S·德塞特布雷特斯
A·迈尔
J·奥戈尔卡
J-P·卡西埃
A·德克乌兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1905880A publication Critical patent/CN1905880A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2004800409427A 2003-11-26 2004-11-25 包含有机化合物的组合物 Pending CN1905880A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52537303P 2003-11-26 2003-11-26
US60/525,373 2003-11-26

Publications (1)

Publication Number Publication Date
CN1905880A true CN1905880A (zh) 2007-01-31

Family

ID=34632977

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800409427A Pending CN1905880A (zh) 2003-11-26 2004-11-25 包含有机化合物的组合物

Country Status (15)

Country Link
US (1) US20070218134A1 (https=)
EP (1) EP1689398A2 (https=)
JP (1) JP2007512287A (https=)
KR (1) KR20060118507A (https=)
CN (1) CN1905880A (https=)
AR (1) AR046458A1 (https=)
AU (1) AU2004292768B2 (https=)
BR (1) BRPI0417011A (https=)
CA (1) CA2546244A1 (https=)
MX (1) MXPA06005953A (https=)
MY (1) MY147202A (https=)
PE (1) PE20050588A1 (https=)
RU (1) RU2006122630A (https=)
TW (1) TW200534876A (https=)
WO (1) WO2005051346A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048701A (zh) * 2010-11-29 2011-05-11 青岛黄海制药有限责任公司 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法
CN111053752A (zh) * 2018-10-16 2020-04-24 南京卓康医药科技有限公司 一种稳定的匹伐他汀钙的肠溶片及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048413B2 (en) * 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US9399064B2 (en) * 2011-04-12 2016-07-26 Sawai Pharmaceutical Co., Ltd. Pitavastatin-containing preparation and method for producing same
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
WO2014129568A1 (ja) 2013-02-22 2014-08-28 ゼリア新薬工業株式会社 腸溶錠
KR102425303B1 (ko) * 2014-08-13 2022-07-25 세다르스-신나이 메디칼 센터 항-메탄생성 조성물 및 그것의 용도
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
IL319156A (en) * 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
CN1440283A (zh) * 2000-04-12 2003-09-03 诺瓦提斯公司 有机化合物的联合形式
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048701A (zh) * 2010-11-29 2011-05-11 青岛黄海制药有限责任公司 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法
CN102048701B (zh) * 2010-11-29 2013-01-09 青岛黄海制药有限责任公司 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法
CN111053752A (zh) * 2018-10-16 2020-04-24 南京卓康医药科技有限公司 一种稳定的匹伐他汀钙的肠溶片及其制备方法

Also Published As

Publication number Publication date
EP1689398A2 (en) 2006-08-16
AU2004292768B2 (en) 2009-04-02
MY147202A (en) 2012-11-14
AR046458A1 (es) 2005-12-07
RU2006122630A (ru) 2008-01-10
TW200534876A (en) 2005-11-01
WO2005051346A3 (en) 2005-08-25
JP2007512287A (ja) 2007-05-17
PE20050588A1 (es) 2005-09-05
KR20060118507A (ko) 2006-11-23
US20070218134A1 (en) 2007-09-20
MXPA06005953A (es) 2006-07-06
AU2004292768A1 (en) 2005-06-09
BRPI0417011A (pt) 2007-02-21
WO2005051346A2 (en) 2005-06-09
CA2546244A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
CN1041794C (zh) 含有一种β－羟基－β－甲基戊二酸单酰辅酶A还原酶抑制剂的稳定的药物组合物
CN1211086C (zh) 雷诺嗪持续释放制剂
CN1298317C (zh) 坦洛新片剂
CN1223341C (zh) 球形体、其制备方法以及药物组合物
CN1250371A (zh) 用于控制释放活性物质的药物组合物
CN1564684A (zh) 药物组合物
CN1406126A (zh) 新型缓释口服制剂
CN1434713A (zh) 环加氧酶－2抑制剂的缓释制剂
CN1864663A (zh) 5,7,14－三氮杂四环[10.3.1.0(2,11).0(4,9)]－十六碳－2(11)3,5,7,9－五烯的药物组合物
CN1874767A (zh) 包含aplindore和其衍生物的缓释药物组合物
CN1681509A (zh) 含拉莫三嗪的缓释制剂
CN1206986C (zh) 包膜马来酸三甲丁酯片剂
CN1993112A (zh) 用于具有高度pH依赖性溶解度的活性成分的控释的药物多层片剂
CN1446535A (zh) 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型
CN1662237A (zh) 控释医药组合物
US20050239884A1 (en) Compositions comprising hmg-coa reductase inhibitor
CN1905880A (zh) 包含有机化合物的组合物
CN1762357A (zh) 一种莫西沙星口服药物制剂及其制备方法
CN1682719A (zh) 一种含有石杉碱甲的肠溶包衣缓释片剂及制备方法
CN1809342A (zh) 含有氟伐他汀和羧甲纤维素钙的片剂
CN1203845C (zh) 含有普鲁芬的药物组合物
CN1433311A (zh) 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物
CN1863509A (zh) 包含麦考酚酸或麦考酚酸钠的多粒子药物组合物和与雷帕霉素的组合
HK1108838A (en) Pharmaceutical multilayer tablet for controlled_release of active ingredients with highly ph-dependent solubility
HK1093683A (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070131